<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121197</url>
  </required_header>
  <id_info>
    <org_study_id>ECR-RET-2014-07</org_study_id>
    <nct_id>NCT02121197</nct_id>
  </id_info>
  <brief_title>Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.</brief_title>
  <acronym>ARTES</acronym>
  <official_title>A Collaborative Retrospective Trial on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients With Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Vision Institute Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association for Innovation and Biomedical Research on Light and Image</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To review the safety and efficacy of injections with Ozurdex (700 μg dexamethasone) in
      clinical practice management of patients with DME.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Best Corrected Visual Acuity (BCVA) from baseline to 4 - 6 months after last injection, with comparison between early (&lt;9 month duration of DME) vs late (≥9 month duration of DME), and naïve vs previously treated patients.</measure>
    <time_frame>6 month</time_frame>
    <description>Percentage of patients with Best Corrected Visual Acuity (BCVA) from baseline to 4 - 6 months after last injection, with comparison between early (&lt;9 month duration of DME) vs late (≥9 month duration of DME), and naïve vs previously treated patients.</description>
  </primary_outcome>
  <enrollment type="Actual">321</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        300-400 patients who have received at least 2 Ozurdex injections for the treatment of DME,
        were followed for at least 6 months after the last injection and with a minimal BCVA of
        20/200 at baseline (before Ozurdex treatment).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (≥18 years) with diabetes

          -  DME in the study eye (if both eyes have DME both eyes will be included in analysis)

          -  BCVA minimum of 20/200 (35 letters)

          -  Central Macular Thickness (CMT) ≥300 µm

          -  Patients with DME who were treated with Ozurdex at least twice (baseline is before the
             first Ozurdex injection).

          -  Follow up of at least 6 months after the last Ozurdex injection given

          -  Complete records including BCVA (OCT and Fluorescein Angiography (FA) if available)
             throughout the follow up

        Exclusion Criteria:

          -  Patients with ME not secondary to Diabetes Mellitus (DM).

          -  Presence of other retinopathies (AMD, RVO) or visually significant ocular morbidity
             (e.g. advanced glaucoma, corneal opacity)

          -  Previous ocular trauma or surgery other than cataract extraction

          -  Intravitreal triamcinolone ≤6 months before baseline

          -  Intravitreal bevacizumab, ranibizumab, or pegaptanib &lt;1 months before baseline

          -  Marked intraocular pressure (IOP) elevation in response to any previous steroid
             treatment

          -  Ocular Hypertension (OHT) in the study eye(s)

          -  IOP &gt;23 mm Hg without antiglaucoma medication

          -  IOP &gt;21 mm Hg with one antiglaucoma medication

          -  Use of 2 or more antiglaucoma medications

          -  Glaucoma - Visual Fields (VF) defect &gt; 4 dB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anat Loewenstein, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Centre Hospitalier Henri Duffaut,</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Croix Rousse University Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Unit, Department of Ophthalmology, CHU Nord, Aix Marseille University</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coscas Eye Clinic</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Lariboisière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department, Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Research Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs</name>
      <address>
        <city>Bari</city>
        <zip>7012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excellence Eye Research Centre University G. d'Annunzio of Chieti-Pescara</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology University Vita Salute - Scientific Institute of San Raffael</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Clinical Trials, Department of Ophthalmology University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.B.Bietti Eye Foundation - IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology University of Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials - Association for Innovation and Biomedical Research on Light and Image</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Retina e Diabetes Ocular de Lisboa (IRL)</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-085</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department, Dos de Maig Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebrón Department of Ophthalmology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Microcirugia Ocular</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vallés Oftalmologia Research</name>
      <address>
        <city>Barcelona</city>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Department, Hospital de LaPaz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Oftalmologia, Hospital Universitario Y Politecnico de la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>460</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Clinic, St Eriks Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-11282</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Clinical Trials Unit Frimley Park Hospital Foundation Trust</name>
      <address>
        <city>Frimley</city>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Diabetic Edema</keyword>
  <keyword>Ozurdex</keyword>
  <keyword>Retrospective</keyword>
  <keyword>European</keyword>
  <keyword>Intra-vitreal injections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

